Clinical Trials


The Division of Nephrology is actively involved in a large number of national and international clinical trials. The following table lists the ongoing clinical trials. New trials are constantly being developed, so check back often and feel free to make an appointment for evaluation even if your disease is not currently represented. Please click on the clinicaltrials.gov link  for more information, or call us if interested in enrolling: 212-305-3273.

PI Title Sponsor Status Trial ID
Gerald Appel, MD  The Nephrotic Syndrome Study Network (NEPTUNE) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Enrolling NCT01240564
Gerald Appel, MD  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis  Biogen Idec Enrolling NCT01499355
Gerald Appel, MD  A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil (MMF) and Corticosteroids in Subjects with Active Class III or IV Lupus Nephritis Bristol-Myers Squibb Enrolling NCT01714817
Gerald Appel, MD  An Open Label Randomized Phase IV Study of the Safety and Efficacy of ACTHAR GEL in Patients with Membranous (Class V) Lupus Nephritis Ohio State University / Questcor Pharmaceuticals Enrolling NCT01926054
Gerald Appel, MD  ATHENA: A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients (RG012-01) Regulus Therapeutics, Inc. Enrolling NCT02136862
Andrew Bomback, MD, MPH A Randomized, Double-Blind, Placebo-Controlled, Dose Assessment Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis ChemoCentryx Enrolling NCT02222155
Pietro Canetta, MD, MSc  A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis Human Genome Sciences Inc., a GSK Company
Enrolling NCT01639339
Pietro Canetta, MD, MSc  A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar® Gel (Acthar) in Treatment-Resistant Subjects with Persistent Proteinuria and Nephrotic Syndrome due to Idiopathic Membranous Nephropathy, QSC01-MN-01 Questcor Pharmaceuticals Enrolling NCT01386554 
David J. Cohen, MD Natural History of Infection Caused by BK Virus (and other Opportunistic Viral Pathogens) in Renal and Renal-Pancreas Transplant Recipients, DMID 11-0071 National Institutes of Health (NIH) Enrolling ---
David J. Cohen, MD Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant (ENLiST Registry)  Bristol Myers Squib Enrolling NCT01386359
David J. Cohen, MD Renal Allograft Tolerance Through Mixed Chimerism Internal Not Yet Inititated at this Site NCT01780454
Anjali Ganda, MD, MS HDL-mediated Cholesterol Efflux in Patients with Chronic Kidney Disease National Institutes of Health (NIH) Enrolling ---
Ali Gharavi, MD Genetic Studies of Chronic Kidney Disease National Institutes of Health (NIH) Enrolling ---
Ali Gharavi, MD Cure Glomerulonephropathy (CureGN) National Institutes of Health (NIH) Enrolling ---
Krzysztof Kiryluk, MD, MS Genetic Studies of Transplant Outcomes National Institutes of Health (NIH) Enrolling ---
Sumit Mohan, MD, MPH iChoose Kidney Decision Aid for End-Stage Renal Disease Patients Emory University Enrolling NCT02235571
Thomas Nickolas, MD, MS Bone Mass & Strength after Kidney Transplant Norman S. Coplon Extramural Grant Enrolling NCT02224144
Jai Radhakrishnan, MD, MS Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (PKD 156-13-211) Otsuka Pharmaceutical Development & Commercialization, Inc. Enrolling by Invitation NCT02251275
Jai Radhakrishnan, MD, MS Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease (PKD 156-13-210)  Otsuka Pharmaceutical Development & Commercialization, Inc. Not Yet Inititated at this Site NCT02160145
Maya Rao, MD Creating a Comprehensive Nutrition Plan in Patients with Advanced Chronic Kidney Disease: a Pilot Study Irving Institute for Clinical and Translational Research Enrolling ---
 
  Research Home   |   Research Programs   |   Basic Science Labs   |  Patient Oriented Research